Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Oseltamivir | Research article

The use of maoto (Ma-Huang-Tang), a traditional Japanese Kampo medicine, to alleviate flu symptoms: a systematic review and meta-analysis

Authors: Tetsuhiro Yoshino, Ryutaro Arita, Yuko Horiba, Kenji Watanabe

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

Influenza is a common viral infection worldwide. Maoto (ma-huang-tang) was developed in ancient China and is used to alleviate flu symptoms. Currently, no meta-analyses have evaluated the efficacy and safety of maoto for alleviating flu symptoms.

Methods

In the present study, we searched MEDLINE/PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, a Japanese database (Ichushi), two Chinese databases (China National Knowledge Infrastructure and VIP), and two Korean databases (Korean Medical database and Korean Association of Medical Journal Editors) for studies published in or before October 2017. Clinical studies that compared maoto plus neuraminidase inhibitors (NAIs) vs. NAIs alone, or maoto alone vs. NAIs alone, were included in the present analysis. The primary outcome measure (efficacy) was the length of time from the start of medication to resolution of influenza symptoms (fever, headache, malaise, myalgia, and chills) and virus isolation. The secondary outcome measures (safety) were as follows: (1) side effects and adverse reactions, such as nausea, abnormal behaviour, or discontinuation of symptomatic treatment; (2) morbidity (complications caused by influenza infection) or mortality; and (3) hospitalisation for any reason.

Results

Twelve relevant studies were identified, including two randomised controlled trials (RCTs, N = 60) and ten non-randomised studies (NRSs, N = 1110). We found that maoto plus NAIs was superior to NAIs alone in terms of the duration of fever in one RCT (P < 0.05, median difference = − 6 h) and four NRSs (P = 0.003, weighted mean difference = − 5.34 h). The duration of symptoms or virus isolation did not differ between maoto and NAIs. No severe side effects or adverse reactions were reported related to maoto or NAIs.

Conclusions

Although we could not reach a definitive conclusion because of the small sample sizes and high risk of bias in the analysed studies, maoto may lower the duration of fever when it is used alone or in combination with NAIs and may be a well-tolerated treatment. More RCTs are needed to determine the efficacy and safety of maoto.
Appendix
Available only for authorised users
Literature
1.
World Health Organization. Influenza. http://​www.​who.​int/​mediacentre/​factsheets/​2003/​fs211/​en/​ (2003). Accessed 10 Jan 2018.
2.
3.
Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis. 2011;203:6–10.CrossRef
4.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–23.CrossRef
5.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965.
6.
Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antivir Res. 2018;157:38–46.CrossRef
7.
Jiang L, Deng L, Wu T. Chinese medicinal herbs for influenza. Cochrane Database Syst Rev. 2013;3 CD004559.
8.
Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011;155:217–25.CrossRef
9.
Mantani N, Andoh T, Kawamata H, Terasawa K, Ochiai H. Inhibitory effect of Ephedrae herba, an oriental traditional medicine, on the growth of influenza a/PR/8 virus in MDCK cells. Antivir Res. 1999;44:193–200.CrossRef
10.
Masui S, Nabeshima S, Ajisaka K, Yamauchi K, Itoh R, Ishii K, et al. Maoto, a traditional Japanese herbal medicine, inhibits uncoating of influenza virus. Evid Based Complement Alternat Med. 2017;2017:1062065.CrossRef
11.
Wolkerstorfer A, Kurz H, Bachhofner N, Szolar OH. Glycyrrhizin inhibits influenza a virus uptake into the cell. Antivir Res. 2009;83:171–8.CrossRef
12.
Hayashi K, Imanishi N, Kashiwayama Y, Kawano A, Terasawa K, Shimada Y, et al. Inhibitory effect of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of influenza a/PR/8 virus in vitro and in vivo. Antivir Res. 2007;74:1–8.CrossRef
13.
Nagai T, Kataoka E, Aoki Y, Hokari R, Kiyohara H, Yamada H. Alleviative effects of a Kampo (a Japanese herbal) medicine "Maoto (ma-Huang-tang)" on the early phase of influenza virus infection and its possible mode of action. Evid Based Complement Alternat Med. 2014;2014:187036.CrossRef
14.
Nishi A, Ohbuchi K, Kushida H, Matsumoro T, Keiko L, Kuroki H, et al. Deconstructing the traditional Japanese medicine “Kampo”: compounds, metabolites and pharmacological profile of maoto, a remedy for flu-like symptoms. NPJ Syst Biol Appl. 2017;3:32.CrossRef
15.
Arita R, Yoshino T, Hotta Y, Miyamoto Y, Osawa I, Takemoto O, et al. National cost estimation of maoto, a Kampo medicine, compared with oseltamivir for the treatment of influenza in Japan. Traditional & Kampo Medicine. 2016;3:59–62.CrossRef
16.
Higgins JP, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. The Cochrane collaboration; 2011.
17.
Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.CrossRef
18.
Fukutomi O, Fukao T, Matsukuma E, Kawamoto N, Omoya K, Kondo K, et al. Experiences where the use of Maoto effectively alleviated influenza symptoms. Science of Kampo Medicine. 2005;29:228–30 [Article in Japanese].
19.
Kawamura K. Assessment of the efficacy of Maoto in influenza patients. The Journal of the Japan Physicians Association. 2007;22:435–8 [Article in Japanese, English abstract available].
20.
Kubo T, Nishimura H. Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type a influenza infection in children. Phytomedicine. 2007;14:96–101.CrossRef
21.
Kawamura K. Maoto shows therapeutic efficacy similar to oseltamivir in treating influenza as determined by viral duration in throat swabs. The Journal of the Japan Physicians Association. 2008;23:418–22 [Article in Japanese, English abstract available].
22.
Taketani T, Hayashi J, Kasai T, Kanai R, Yamaguchi S, Nishimura N, et al. Investigation of the effectiveness of Maoto for pediatric influenza. Child Health. 2008;11:114–8 [Article in Japanese].
23.
Kawamura K, Miwa Y. Assessment of the efficacy of oseltamivir and Maoto in influenza a (a/H1N1, a/H3N2) patients. The Journal of the Japan Medical Association. 2009;138:1391–6 [Article in Japanese].
24.
Mori Y. Experiences with Kampo treatment for a new type of influenza. Journal of Kampo Medicine. 2010;57:1655–62 [Article in Japanese].
25.
Nabeshima S, Kashiwagi K, Ajisaka K, Kitajima K, Masui S, Ikematsu H, et al. A comparison of oseltamivir with maoto, a traditional herbal medicine, for the treatment of adult seasonal influenza a. J. Transl. Med. 2010;27:148–56.
26.
Saita M, Naito T, Boku S, Watanabe Y, Suzuki M, Oka F, et al. The efficacy of ma-huang-tang (maoto) against influenza. Health. 2011;3:300–3.CrossRef
27.
Suzuki E, Ichihara K. Impact of Japanese herbal medicine, Mao-to, compared to oseltamivir on fever course in children with influenza type a. The journal of ambulatory and general pediatrics of Japan, vol. 14; 2011. p. 248–53. [Article in Japanese, English abstract available]
28.
Tsuji Y, Morita K, Ichihashi I, Itabashi K. Effects of Maoto in combination therapy for pediatric influenza. Science of Kampo Medicine. 2011;35:158–60 [Article in Japanese].
29.
Nabeshima S, Kashiwagi K, Ajisaka K, Masui S, Takeoka H, Ikematsu H, et al. A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza. J Infect Chemother. 2012;18:534–43.CrossRef
30.
Toriumi Y, Kamei T, Murata K, Takahashi I, Suzuki N, Mazda O. Utility of Maoto in an influenza season where reduced effectiveness of oseltamivir was observed - a clinical, non-randomized study in children. Forschende Komplementarmedizin. 2012;19:179–86.CrossRef
31.
Jin X, Uchiyama M, Zhang Q, Watanabe T, Niimi M. The smell of Tokishakuyaku-san (TJ-23) induces generation of regulatory T cells and prolongation of survival of fully allogeneic cardiac grafts in mice. Transplant Proc. 2012;44:1070–2.CrossRef
32.
The Japan Geriatrics Society. Guidelines for medical treatment and its safety in the elderly. Tokyo: Medical View Co., Ltd; 2015. p. 139–51. [Article in Japanese]
33.
Campigotto A, Mubareka S. Influenza-associated bacterial pneumonia; managing and controlling infection on two fronts. Expert Rev Anti-Infect Ther. 2015;13:55–68.CrossRef
34.
Yoshino T, Takada T, Horiba Y, Watanabe K. Classification of acute phase febrile upper respiratory tract infection: retrospective chart review. Traditional and Kampo Medicine. 2017;4:31–7.CrossRef
Metadata
Title
The use of maoto (Ma-Huang-Tang), a traditional Japanese Kampo medicine, to alleviate flu symptoms: a systematic review and meta-analysis
Authors
Tetsuhiro Yoshino
Ryutaro Arita
Yuko Horiba
Kenji Watanabe
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2474-z

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue

Research article

Inhibitory effects of Azadirachta indica secondary metabolites formulated cosmetics on some infectious pathogens and oxidative stress radicals

Research article

Antimicrobial characteristics of Berberine against prosthetic joint infection-related Staphylococcus aureus of different multi-locus sequence types

Research article

Evaluating the protective potency of Acacia hydaspica R. Parker on histological and biochemical changes induced by Cisplatin in the cardiac tissue of rats

Research article

The fallacy of enzymatic hydrolysis for the determination of bioactive curcumin in plasma samples as an indication of bioavailability: a comparative study

Research article

Antioxidants and α-glucosidase inhibitors from Neptunia oleracea fractions using 1H NMR-based metabolomics approach and UHPLC-MS/MS analysis

Research article

Panax notoginseng saponins promote liver regeneration through activation of the PI3K/AKT/mTOR cell proliferation pathway and upregulation of the AKT/Bad cell survival pathway in mice